Your browser doesn't support javascript.
loading
Effects of selective serotonin reuptake inhibitors (SSRIs) on suicide: A network meta-analysis of double-blind randomized trials.
Li, Yuling; Chen, Chengfeng; Chen, Qinghua; Yuan, Shiqi; Liang, Wanyuan; Zhu, Yikang; Zhang, Bin.
Afiliação
  • Li Y; The Mental Health College of Guangzhou Medical University, Guangzhou, PR China; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, PR China.
  • Chen C; The Mental Health College of Guangzhou Medical University, Guangzhou, PR China; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, PR China.
  • Chen Q; The Mental Health College of Guangzhou Medical University, Guangzhou, PR China; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, PR China.
  • Yuan S; The Mental Health College of Guangzhou Medical University, Guangzhou, PR China; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, PR China.
  • Liang W; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, PR China.
  • Zhu Y; Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Zhang B; Institute of Mental Health, Tianjin Anding Hospital, Tianjin Medical University, Tianjin, PR China. Electronic address: zhang.bin845@foxmail.com.
Psychiatry Res ; 336: 115917, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38663222
ABSTRACT
The relationship between the use of selective serotonin reuptake inhibitors (SSRIs) and suicide risk in patients with mental disorders remains controversial. We conducted a network meta-analysis to examine the effects of SSRIs on suicide risk in patients with mental disorders. A comprehensive search was conducted across PubMed, Web of Science, PsycINFO, CENTRAL, Wanfang Database, and China National Knowledge Infrastructure for articles published until December 19, 2023. The main outcomes were suicidal ideation and instances of suicidal behavior. We included 29 double-blind randomized trials in our analysis. The findings suggest that SSRIs primarily offer short-term protection against suicidal ideation. By week 2, paroxetine, fluoxetine, escitalopram, and non-SSRI treatments were linked to a decreased suicide risk compared with a placebo, with the exception of sertraline. This protective effect was diminished by week 8. In contrast, studies on instances of suicidal behavior from weeks 1 to 10 found no significant difference in efficacy between SSRIs, non-SSRIs, and placebo. These results indicate that SSRIs may offer short-term protection against suicidal ideation. However, their long-term effectiveness in mitigating suicidal ideation and preventing suicidal behaviors is limited.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Inibidores Seletivos de Recaptação de Serotonina / Ideação Suicida / Metanálise em Rede Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Inibidores Seletivos de Recaptação de Serotonina / Ideação Suicida / Metanálise em Rede Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article